Viread’s explosive growth to KRW 100 billion prescriptions

‘Viread,’ the new star of the hepatitis B treatment market, will list its name for the gigantic products which record KRW 100 billion outpatient prescriptions.

Until the last year, products exceeding annual KRW 100 billion outpatient prescriptions were only ‘Baraclude’ and ‘Lipitor.’

By the 3^rd quarter of the year, ‘Viread’ has continued an explosive growth as recording a KRW 30 billion quart...